Investment Newsletters

H.C. Wainwright

H.C. Wainwright Reiterates Buy On La Jolla Following 2Q14 Results; Keeps $20 PT

In a research note released today, H.C.

Ben Mahaney, Editor — August 15, 2014, 12:28 PM EDT

H.C. Wainwright Reiterates Buy On RXi Pharmaceuticals Following 2Q14 Update

In a research note published today, H.C.

Ben Mahaney, Editor — August 15, 2014, 11:57 AM EDT

Shares Of Keryx Remain Undervalued And Represent Upside, Says H.C. Wainwright

In a research note published August 8, H.C.

Editor Ben Weinberg — August 11, 2014, 2:41 PM EDT

H.C. Wainwright Reiterates Buy On CytRx, Following 2Q14 Update

In a research report released August 8, H.C.

Editor Ben Weinberg — August 11, 2014, 11:18 AM EDT

Celsion Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research report published August 8th, H.C.

Editor Ben Weinberg — August 11, 2014, 10:11 AM EDT

Spectrum Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research report released August 8, H.C.

Editor Ben Weinberg — August 11, 2014, 9:07 AM EDT

H.C. Wainwright Reiterates Buy On Aeterna Zentaris Following 2Q14 Business Update

In a report issued today, H.C.

Ben Mahaney, Editor — August 8, 2014, 1:46 PM EDT

H.C. Wainwright Reiterates Buy On BioCryst Pharmaceuticals, Sees 84% Upside

In a research report released yesterday, H.C.

Editor Ben Weinberg — August 7, 2014, 2:28 PM EDT

OXiGENE Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research report released yesterday, H.C.

Editor Ben Weinberg — August 7, 2014, 11:32 AM EDT

EDAP: We Believe A Positive FDA Decision Is Now Unlikely, Says H.C. Wainwright

The Gastroenterology Urology Device Panel, which Wednesday reviewd EDAP TMS’s (EDAP) Ablatherm Pre Marketing Approval (PMA) application for the primary treatment of low-risk, …

Ben Mahaney, Editor — August 1, 2014, 3:50 PM EDT

« 1 … 17 18 19 20 21 »